Literature DB >> 9894879

Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.

J B Schulz1, M Skalej, D Wedekind, A R Luft, M Abele, K Voigt, J Dichgans, T Klockgether.   

Abstract

By using three-dimensional magnetic resonance imaging-based volumetry, we studied atrophy of the caudate nucleus, putamen, brainstem, and cerebellum in patients with idiopathic Parkinson's syndrome (IPS, n = 11), progressive supranuclear palsy (PSP, n = 6), and multiple system atrophy with predominant parkinsonism (MSA-P, n = 12) or ataxia (MSA-C, n = 17). Patients were compared with a total of 46 controls, of whom 16 were age matched. Mean striatal, cerebellar, and brainstem volumes were normal in patients with IPS. We found significant reductions in mean striatal and brainstem volumes in patients with MSA-P, MSA-C, and PSP, whereas patients with MSA-C and MSA-P also showed a reduction in cerebellar volume. On an individual basis, volumes of structures in patients with MSA and PSP showed an extensive overlap with the normal range with the exception of brainstem volumes in patients with MSA-C. Therefore, groups could not be discriminated on the basis of individual structure volumetry. Application of stepwise discriminant analysis, however, allowed discrimination of all 12 patients with MSA-P, 15 of 17 patients with MSA-C, and 5 of 6 patients with PSP from the normal and IPS cohorts. However, patients with IPS could not be separated from controls and patients with MSA-P could not be separated from patients with PSP. In conclusion, total intracranial volume-normalized magnetic resonance imaging-based volumetric measurements provide a sensitive marker to discriminate typical and atypical parkinsonism.

Entities:  

Mesh:

Year:  1999        PMID: 9894879

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  63 in total

1.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

2.  Magnetic resonance imaging in progressive supranuclear palsy.

Authors:  M Stamelou; S Knake; W H Oertel; G U Höglinger
Journal:  J Neurol       Date:  2010-12-22       Impact factor: 4.849

Review 3.  How to diagnose MSA early: the role of magnetic resonance imaging.

Authors:  K Seppi; M F H Schocke; G K Wenning; W Poewe
Journal:  J Neural Transm (Vienna)       Date:  2005-07-06       Impact factor: 3.575

4.  In vivo basal ganglia volumetry through application of NURBS models to MR images.

Authors:  Giuseppe Anastasi; Giuseppina Cutroneo; Francesco Tomasello; Sebastiano Lucerna; AntonGiulio Vitetta; Placido Bramanti; Paolo Di Bella; Anna Parenti; Andrea Porzionato; Veronica Macchi; Raffaele De Caro
Journal:  Neuroradiology       Date:  2006-03-28       Impact factor: 2.804

Review 5.  Human gene therapy and imaging in neurological diseases.

Authors:  Andreas H Jacobs; Alexandra Winkler; Maria G Castro; Pedro Lowenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

6.  Tracking the neurodegeneration of parkinsonian disorders--a pilot study.

Authors:  C Nilsson; K Markenroth Bloch; S Brockstedt; J Lätt; H Widner; E-M Larsson
Journal:  Neuroradiology       Date:  2007-01-03       Impact factor: 2.804

7.  Performing label-fusion-based segmentation using multiple automatically generated templates.

Authors:  M Mallar Chakravarty; Patrick Steadman; Matthijs C van Eede; Rebecca D Calcott; Victoria Gu; Philip Shaw; Armin Raznahan; D Louis Collins; Jason P Lerch
Journal:  Hum Brain Mapp       Date:  2012-05-19       Impact factor: 5.038

Review 8.  Neuroimaging in Parkinson's disease.

Authors:  David J Brooks
Journal:  NeuroRx       Date:  2004-04

9.  H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers.

Authors:  Elisa Canu; Marina Boccardi; Roberta Ghidoni; Luisa Benussi; Cristina Testa; Michela Pievani; Matteo Bonetti; Giuliano Binetti; Giovanni B Frisoni
Journal:  Eur J Hum Genet       Date:  2008-10-15       Impact factor: 4.246

10.  Use of the Putamen/Caudate Volume Ratio for Early Differentiation between Parkinsonian Variant of Multiple System Atrophy and Parkinson Disease.

Authors:  Ha Y Shin; Suk Y Kang; Jae H Yang; Hyun-Sook Kim; Myung-Sik Lee; Young H Sohn
Journal:  J Clin Neurol       Date:  2007-06-20       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.